Antihipertenzivna terapija

Antihypertensive i rizikand
Therapy od the
pojave dijabetesa
Risk of Diabete
14
Relative Risk of Diabetes

n = 1462 Women p<0.001

12

10

8
p<0.001
6
p<0.01
4

0
Untreated Diuretic -Blocker Diuretic +
NT and HT -Blocker
Patients
HT Subjects Treated
Statistically significant difference from no treatment.
Adapted from BengtssonC. et al Br Med J. 1984:289:1495-1497
 ALPINE Study
Novi sluajevi metabolikog sindroma
No of pts.
(n=362)
20 p<0.01 HCTZ+BBL
18 Candesartan
16 +CCB
14
12
10
8
6
4
2
0
Baseline 12 month
Lindholm LH, J Hypertens 2003
Promene lipidnog profila sa nebivololom i atenololom
posle 12 nedelja leenja esencijalne hipertenzije

TC LDL-C LDL-C/HDL-C TG
20
+16.3
15

10 +8.7

% 0
-2.4 -2.7 -2.0
-5 -4.6
-10
-10.1
-11.5
-15 Nebivolol (5 mg)
Atenolol (50 mg)
-20

Pesant et al. Amer J Therap 1999

 PROMENA GLIKEMIJE (OGTT)
POSLE 12 NEDELJA LEENJA NEBIVOLOLOM ILI ATENOLOLOM
KOD NORMOMETABOLIKIH HIPERTONIARA

AUC Glucose
Glucose
(0-2h)
10 +9.4
%
8

+3.8
4

2 +1.3
+1.0 Nebivolol (5 mg)
Atenolol (50 mg)
0

Pesant et al., J Therap 1999; 6: 137

 Efekat nebivolol ili metoprolola na insulinsku
rezistenciju kod hipertenzivnih pacijenata

baseline

6 months

baseline
6 months

Change in insulin resistance, as measured by the HOMA-IR

(HOmeostasis Model Assessment) Insulin Resistance

p not significant vs baseline

# p=0.008 vs baseline,
p=0.003 vs metoprolol

Celik et al, J. Hypertens, 2006; 24:591-6

Pojava novih sluajeva dijabetesa u SENIORS studiji

2
1.6%
% event rates

1.3%
Placebo
1
Nebivolol

0
Placebo Nebivolol
Rossei EA, SENIORS, 2007
Po prvi put jasna razlika izmeu
konvencionalnih BB i nebivolola